(Q33650232)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

review article

1 reference

title

Multidrug resistance in oncology: diagnostic and therapeutic approaches (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

main subject

multiple drug resistance

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

author name string

Robert J

series ordinal

1

1 reference

28 July 2017

publication date

1 June 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Investigation

8 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

page(s)

536-545

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

8 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Quantitation of multidrug resistant MDR1 transcript in acute myeloid leukaemia by non-isotopic quantitative cDNA-polymerase chain reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Expression of MDR1/P glycoprotein in human sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Multidrug-resistance modulation in metastatic breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Pharmacological considerations in the modulation of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Reversal of drug-resistance in multiple myeloma with verapamil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Phase I and pharmacokinetic study of D-verapamil and doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.1999.00495.X

10.1046/J.1365-2362.1999.00495.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10354216%20AND%20SRC:MED&resulttype=core&format=json

release_5fpuv73mp5hnzbjhdqiarmz5u4

8 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5fpuv73mp5hnzbjhdqiarmz5u4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference